Biotechnology company MEDIPOST Inc said on Friday that it has submitted an Investigational New Drug (IND) amendment to the US Food and Drug Administration (FDA) to support the initiation of a Phase III clinical trial evaluating its investigational cell therapy targeting knee osteoarthritis.
The therapy is an allogeneic, umbilical cord blood-derived mesenchymal stem cell treatment designed to address symptomatic cartilage defects in affected patients.
Patient enrolment for the Phase III study is expected to begin in the first half of 2026.
Knee osteoarthritis remains a major cause of pain and mobility loss, underscoring the need for treatments that extend beyond symptom management. The trial aims to further evaluate the potential of regenerative cell therapy in meeting this clinical need.
Iterion Therapeutics reports first patient dosed in clinical study of tegavivint
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1
Innocan Pharma reports findings from clinical study of LPT-CBD in dogs
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
Median Technologies secures FDA clearance for AI lung cancer screening software
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
Ascentage Pharma receives China IND clearance for BTK degrader APG‑3288
FDA issues EUA for Boehringer Ingelheim's IVOMEC (ivermectin) 1% Injection
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
Hologic receives FDA approval for Aptima HPV assay as primary screening option
AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer